服用恩瑞格要注意什么事项？

The results of the TELESTO study released at the ASH 2018 conference proved that it can continuously reduce serum ferritin levels and at the same time reduce the risk of heart function damage, liver function damage, transformation to leukemia and other events by 36.4%. So, what should you pay attention to when taking Cipla India?

India's Cipla is the second largest pharmaceutical company in India, with strong financial and scientific research capabilities. Especially its cheap anti-AIDS and anti-cancer drugs are very popular among patients in developing countries. A generic drug is a copy of a brand-name drug that is identical in dosage, safety, potency (regardless of how it is taken), quality, effects, and indications. Enreg is one of these generic drugs.

1. Do not use this product if you are allergic or sensitive to any ingredient in Enrige.

2. People taking Enriga have experienced gastrointestinal bleeding and ulcers, including some children and adolescents.

3. People at risk of renal failure include the elderly, those with kidney disease, and those taking drugs that affect kidney function.

4. Using Enrige with blood thinners or other drugs that irritate the gastrointestinal tract, such as glucocorticoids and bisphosphonates, will increase the risk.

5. Using Enrige may cause skin rash. If the condition is severe, the medication may need to be stopped temporarily and then restarted at a lower dose.

6. Dose adjustment may be required, as Enriga is associated with potentially severe reductions in white blood cell and platelet counts, especially in people with pre-existing blood abnormalities.

7. Enrig can cause hearing loss and eye disease only in rare cases. A comprehensive hearing and eye examination should be performed before starting use of Enrig and, thereafter, yearly.

8. Most of the reactions appear in the first month of treatment. Liver function should be checked regularly while taking Enrige. In some cases, patients who have had a fatal reaction while taking Enriga may develop kidney failure. Patients with renal failure or who are at significant risk for renal failure should have periodic kidney function tests while taking Enriga.

It is currently the only oral iron chelator developed by Novartis. Enrig was approved by the FDA in November 2005 for use in patients 2 years and older with chronic iron overload caused by blood transfusions.